Catalyze Digital Biomarker Innovation Through Collaboration

Industry and academia each play important roles in advancing wearable technologies and digital biomarkers to develop life-changing drugs and therapies. Still, successful relationships between the two groups are not nearly as prevalent as they could – or should – be. In this presentation, Kate Lyden, VivoSense Chief Science Officer, discusses the motivation for academia and industry to work together, where the overlap lies, and opportunities for moving forward together.

Here are a few key takeaways from the presentation about how academia and industry can collaborate to improve patient outcomes.

  • Industry-sponsored investigations: Thoughtful and structured relationships that go beyond sharing code and algorithms.
  • Consultancy engagements. Industry seeking the expertise of academics and academics identifying the use cases industry should support.
  • Joint appointments. Opportunities for adjunct science faculty positions in the industry.
  • Cost-sharing or no-cost pledges of support: Industry partners’ letters of support or matched funding to help academic researchers get the funding they need.
  • Hire post-docs and academics: Build bridges between industry and academic research laboratories.

At the end of the rainbow, the pot of gold is a developed Industry-Academia Consortium. Industry gets experts in developing real-world digital clinical measures, and academics get the opportunity to work on relevant challenges and problems. It’s a win-win that will catalyze wearables and digital biomarker innovation.

4 Key Principles of Digital Biomarker Development eBook Read it Today!

Kate Lyden, PhD

Kate Lyden, PhD

Kate Lyden, PhD, VivoSense Chief Science Officer, holds degrees in Kinesiology and Applied Physiology and has extensive research experience developing, validating, and using wearable sensors.

Follow on:

Stay Connected